ESLA — Estrella Immunopharma Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Estrella Immunopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Cash and Short Term Investments | 4.09 | 2.48 | 4.17 | 1.38 |
| Net Total Receivables | 0 | 0.273 | 0 | — |
| Prepaid Expenses | ||||
| Total Current Assets | 4.92 | 2.75 | 4.45 | 1.68 |
| Other Long Term Assets | ||||
| Total Assets | 4.92 | 3.03 | 4.45 | 3.18 |
| Accounts Payable | ||||
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.947 | 9.76 | 0.181 | 13.5 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 0.962 | 9.77 | 0.181 | 13.5 |
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Treasury Stock | ||||
| Total Equity | 3.96 | -6.74 | 4.27 | -10.4 |
| Total Liabilities & Shareholders' Equity | 4.92 | 3.03 | 4.45 | 3.18 |
| Total Common Shares Outstanding |